AMENDMENT NO. 1 TO AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • May 10th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the “Amendment No. 1”), effective as of October 22, 2015 (the “Amendment No. 1 Effective Date”), is entered into by and between Fred Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (“FHCRC”), and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (“LICENSEE”).
JUNO THERAPEUTICS, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT NOTICE OF GRANT OF RESTRICTED STOCK UNITSRestricted Stock Unit Award Agreement • May 10th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Washington
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Grant of Restricted Stock Units (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Unit Grant, and any appendices and exhibits attached thereto (all together, the “Award Agreement”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • May 10th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amended and Restated Patent and Technology License Agreement (the “Amendment No. 1”), effective as of October 22, 2015 (the “Amendment No. 1 Effective Date”), is entered into by and between Fred Hutchinson Cancer Research center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (“FHCRC”), and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle, Washington 98019 (“LICENSEE”).
JUNO THERAPEUTICS, INC. STOCK GRANT AWARD AGREEMENT NOTICE OF GRANT OF STOCK AWARDStock Grant Award Agreement • May 10th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Washington
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Grant Award Agreement, including the Notice of Grant of Stock Award (the “Notice of Grant”), the Terms and Conditions of Stock Award, and any appendices and exhibits attached thereto (all together, the “Award Agreement”).
AMENDMENT NO. 2 to AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • May 10th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Amended and Restated Patent and Technology License Agreement (“Amendment No. 2), effective as of March 25, 2016 (the “Amendment No. 2 Effective Date”), is entered into by and between Fred Hutchinson Cancer Research Center, a Washington state non-profit organization having offices at 1100 Fairview Avenue North, Seattle, Washington 98109 (“FHCRC”) and Juno Therapeutics, Inc., a Delaware corporation having offices located at 307 Westlake Avenue North, Suite 300, Seattle Washington 98109 (“LICENSEE”).
